AbbVie Q3 EPS rises to $2.37; Q3 net revenues climb 10% to $17.4 billion
Bitget2026/10/30 11:48- AbbVie’s third-quarter GAAP diluted earnings per share rose to $2.37 from a year earlier.
- Net revenues climbed 10% to $17.4 billion.
- Immunology net revenues increased 16% to $9.17 billion, while neuroscience net revenues advanced 19% to $3.39 billion.
- The acquisition of Apogee Therapeutics was completed, expanding the immunology pipeline.
- The quarterly cash dividend will rise 5% to $1.82 per share, beginning with the payment payable February 16, 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Crypto prices
More
